Sign in

CBST on NASDAQ

Cubist Pharmaceuticals

Logo: Grmike, Public domain, via Wikimedia Commons5

Defunct American pharmaceutical company

Cubist Pharmaceuticals, Inc. was an American biopharmaceutical company that targeted pathogens like MRSA. The company employed 638 people, mostly in Lexington, Massachusetts. On 8 December 2014, Merck & Co. acquired Cubist for $102 per share in cash ($8.4 billion).3 Its shares trade on NASDAQ under the symbol CBST.1 Wikipedia text CC BY-SA 4.0

Price unavailable

Last updated Oct 21, 2026.

Overview

1992Founded1

Compare with another stock.

  • TickerCBST on NASDAQ1
  • IndustryPharmaceutical Preparations1
  • HeadquartersLexington1
  • Websitewww.cubist.com
  • Incorporated inDE6
  • Business address65 Hayden Avenue, Lexington, Ma 024216
  • Filer categoryLarge accelerated filer6
  • Legal formLimited Liability Company4
  • LEI5493005UQEY3UCKO3G184
  • StatusActive4
  • LEI statusLapsed (not renewed)4
  • Registered addressC/O The Corporation Trust Company, 19801 Wilmington, United States4
  • Registered withDivision of Corporations, Department of State, 22964204

See how the biggest companies compare on our leaderboards

Cubist Pharmaceuticals, Inc. was an American biopharmaceutical company that targeted pathogens like MRSA.3

Corporate structure

Cubist Pharmaceuticals is part of a group headed by Merck & Co.. 347 entities, 69 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

  • Merck & Co. Rahway, New Jersey, United States
    • Cubist Pharmaceuticals Lexington, Massachusetts, United States
    • MSD Sharp & Dohme GmbH München, Germany
    • Merck (Japan) Subsidiary · Tokyo, Japan
    • Merck Sharp & Dohme Latvija, SIA Subsidiary · Riga, Latvia
    • Merck Sharp & Dohme, UAB Subsidiary · Vilnius, Lithuania
    • MSD (Netherlands) Subsidiary · Amsterdam, Netherlands
    • MSD Norway AS Subsidiary · Drammen, Norway
    • Sirna Therapeutics Subsidiary · San Francisco
    • 7728026 Canada Inc. Subsidiary · Canada
    • Abceutics, Inc. Subsidiary · Delaware, United States
    • Abmaxis Inc. Subsidiary · Delaware, United States
    • Acceleron Pharma Inc. Subsidiary · Delaware, United States
    • Afferent Pharmaceuticals, Inc. Subsidiary · Delaware, United States
    • Agrident GmbH Subsidiary · Germany
    • Allflex (China) Intelligent Technology Co. Ltd. Subsidiary · China
    • Allflex Argentina S.A. Subsidiary · Argentina
    • Allflex Australia Pty. Ltd. Subsidiary · Australia
    • Allflex Dan-Mark ApS Subsidiary · Denmark
    • Allflex Europe S.A.S. Subsidiary · France
    • Allflex Group Germany GmbH Subsidiary · Germany
    • ALLFLEX INDIA PRIVATE LIMITED Subsidiary · Gurugram, India
    • Allflex Maroc S.A.R.L. Subsidiary · Morocco
    • Allflex New Zealand Subsidiary · New Zealand
    • Allflex Polska Spolka z ograniczona odpowiedzialnoscia Subsidiary · Poland
    • Allflex Romania S.R.L. Subsidiary · Romania
    • and 316 more

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; subsidiaries, stakes and holdings from Wikidata (CC0). Each entity in the chart links to its source.

What it owns

What Cubist Pharmaceuticals reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$255.5M8 Dec 31, 2013$230.0M8 Dec 31, 2012+11.1%
Accumulated depreciation$78.0M8 Dec 31, 2013$63.5M8 Dec 31, 2012+22.7%
Property and equipment, net$177.5M8 Dec 31, 2013$166.5M8 Dec 31, 2012+6.7%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$91.1M8 Dec 31, 2013$104.0M8 Dec 31, 2012−12.5%
Debt securities available for sale$470.3M8 Dec 31, 2013$815.2M8 Dec 31, 2012−42.3%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$383.0M8 Dec 31, 2013$114.1M8 Dec 31, 2012+235.6%
Finite-lived intangibles, gross$791.4M8 Dec 31, 2013$194.4M8 Dec 31, 2012+307.1%
Finite-lived intangibles, net$721.1M8 Dec 31, 2013$152.8M8 Dec 31, 2012+371.8%

Inventory

ItemLatestA year beforeChange
Inventory, total$57.7M8 Dec 31, 2013$41.9M8 Dec 31, 2012+37.5%
Raw materials$17.9M8 Dec 31, 2013$9.1M8 Dec 31, 2012+96.1%
Work in process$8.1M8 Dec 31, 2013$8.5M8 Dec 31, 2012−4.5%
Finished goods$31.7M8 Dec 31, 2013$24.3M8 Dec 31, 2012+30.1%

The story

Cubist was founded in May 1992 by John K. Clarke, Paul R. Schimmel, Ph.D. and Barry M. Bloom, Ph.D, all of whom were also directors.

Cubist appeared on Fortune 2010’s List of fastest growing companies, and was named to the 2010 Deloitte Technology Fast 500.

In 2011, the company acquired Adolor, maker of a drug for treatment of constipation.

In July 2013, Cubist Pharmaceuticals agreed to purchase Trius Therapeutics and Optimer Pharmaceuticals for around $1.6 billion.

In 2014, succeeding Michael Bonney as President, Robert J. Perez, was announced to take leadership on January 1, 2015.

In January 2015, Cubist Pharmaceuticals became a wholly owned subsidiary of Merck & Co.

From Wikipedia’s article on Cubist Pharmaceuticals, shared under CC BY-SA 4.0.7

Leadership

Who has led Cubist Pharmaceuticals, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Michael W. Bonney2006–2015
  2. Robert J. Perez2015

President

  1. Michael W. Bonney2006–2013
  2. Robert J. Perez2012–2014

Chief financial officer

  1. David W. J. McGirr2006–2013
  2. Michael John Tomsicek2013–2015

Chief operating officer

  1. Robert J. Perez2009–2014
  2. Patrick V.j.j. Vink2015
1995200020052010201520202025
Board members and other officers (28)

Products and brands

The company developed Cubicin (daptomycin) for injection, the first antibiotic in a class of anti-infectives called lipopeptides. In 2011, Cubist settled a patent litigation with Teva Pharmaceutical Industries regarding Cubicin.

In April 2011 it reached a deal with Optimer Pharmaceuticals in which its class of bacterium-fighting drugs will be co marketed with Optimer's Fidaxomicin/Dificid (for $15 million per year).

In 2011, its product pipeline focused on gram-negative bacterial infections, Clostridioides difficile infection, and respiratory syncytial virus.

Tedizolid was approved by the US Food and Drug Administration on June 20, 2014.

From Wikipedia’s article on Cubist Pharmaceuticals, shared under CC BY-SA 4.0.7

Timeline

  1. Jan 5, 2015New chief executive Robert J. Perez becomes CEO9
  2. 2015Dissolved Dissolved1
  3. Jan 5, 2006New chief executive Michael W. Bonney becomes CEO10
  4. 1992Founded Founded1

Calendar

Drug trials and FDA: recently

  1. May 12, 2026FDA approved a new use FDA approved an efficacy supplement for Zerbaxa (ceftolozane sulfate), a new use or patient group (NDA 206829, supplement 23).43
  2. Apr 4, 2025FDA approved a new use FDA approved an efficacy supplement for Sivextro (tedizolid phosphate), a new use or patient group (NDA 205435, supplement 16).44

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar

SEC filer profile

How Cubist Pharmaceuticals is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARCUBIST PHARMACEUTICALS INC2
  • CIK0000912183
  • Employer ID (EIN)22-31920852
  • Filer statusLarge accelerated filer2
  • Incorporated inDelaware2
  • Fiscal year endsDecember 312
  • Industry code (SIC)2834 Pharmaceutical Preparations2
  • Business address65 Hayden Avenue, Lexington, MA 024212
  • Phone781-860-86602
  • Shares outstanding76,295,299 as of Nov 3, 201445
  • Public float$3.2B as of Jun 28, 20138
  • On EDGAR sinceJun 25, 19962
  • Filings1,497 in all: 4 (682), 8-K (241), SC 13G/A (99), 10-Q (55), SC 13G (41), S-8 POS (28), S-8 (24), 3 (23)2
    All 59 form types

    CT ORDER (23), SC TO-T/A (23), DEF 14A (18), 10-K (16), CORRESP (16), UPLOAD (16), 424B3 (12), SC TO-C (12), POS AM (10), S-3 (10), 425 (8), DEFA14A (8), S-3/A (8), 8-K/A (7), ARS (7), SC 13D (7), 10-Q/A (6), 424B4 (6), 424B5 (6), EFFECT (6), SC 13D/A (6), 10-K/A (5), 4/A (5), 5 (5), PRE 14A (5), S-1/A (5), SC 14D9/A (5), 3/A (3), RW (3), S-3MEF (3), SC TO-T (3), SC14D9C (3), 10-K405 (2), 15-12B (2), 25 (2), 8-A12G (2), 8-A12G/A (2), FWP (2), S-1 (2), S-3ASR (2), SC TO-I/A (2), 15-12G (1), 25-NSE (1), 424B1 (1), 8-A12B (1), CERTNAS (1), S-1MEF (1), S-4 (1), S-4/A (1), SC 14D9 (1), SC TO-I (1)

  • Latest filingsAnnual report (10-K) Feb 25, 2014
    Quarterly report (10-Q) Nov 7, 2014
    Proxy statement (DEF 14A) Apr 21, 2014
    Latest 8-K (8-K) Jan 21, 2015

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45